{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:54:04Z","timestamp":1793357644079,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Immune checkpoint inhibitors (ICIs) are efficacious in many cancer types but can produce immune-related adverse events (irAEs). As such, patients with preexisting autoimmune disorders are often excluded from clinical trials, although subsequent studies have shown that many of these patients have acceptable ICI tolerance. The safety and efficacy of ICIs among patients with preexisting neurologic autoimmune disorders (NAIDs) is not well characterized.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the safety and clinical outcomes associated with ICI therapy among patients with NAIDs.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter retrospective cohort study included patients with cancer who were treated with ICIs between October 2013 and May 2023 and had preexisting multiple sclerosis (MS), myasthenia gravis (MG), Guillain-Barr\u00e9 syndrome (GBS), and other NAIDs as well as a control cohort of patients with Parkinson disease (PD).<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n ICI therapy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Demographic and clinical characteristics (neurologic disability, active or recent immunosuppression), ICI outcomes (response, progression-free survival [PFS], and overall survival [OS]), and safety outcomes (NAID exacerbation, irAEs) were collected.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 135 patients were included; the median (range) age was 72 (40-88) years, 84 (62%) were men, and 51 (38%) were women. A total of 45 patients had MS; 18, MG; 10, GBS; 5, another NAID; and 57, PD. Exacerbations occurred most frequently in MG (12 of 18 patients [67%]), often resulting in hospitalization (6 [50%]) or death (2 [17%]), with much lower rates in the MS cohort (8 of 45 patients [18%]). Ten patients with a history of GBS tolerated ICI without exacerbations, although 1 developed a fatal case of Lambert Eaton myasthenic syndrome following ICI treatment. No differences in response rate, PFS, or OS were observed between NAID groups.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of ICI use in NAIDs, patients with MG had frequent and more severe exacerbations, while those with MS had few exacerbations. No obvious differences in survival between groups were observed. ICI may be an option for many patients with appropriate oncologic indications and preexisting NAIDs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.13727","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:00:44Z","timestamp":1749034844000},"page":"e2513727","source":"Crossref","is-referenced-by-count":26,"title":["Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders"],"prefix":"10.1001","volume":"8","author":[{"given":"Kylie","family":"Fletcher","sequence":"first","affiliation":[{"name":"Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Machaalani","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razane","family":"El Hajj Chehade","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin H.","family":"Nassar","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashad","family":"Nawfal","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manos","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Royal North Shore Hospital, Sydney, New South Wales, Australia"},{"name":"Mater Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Aboubakar-Nana","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[{"name":"University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom"},{"name":"Division of Oncology, Department of Translational Medicine (DIMET), University of Piemonte Orientale, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Johnson","sequence":"additional","affiliation":[{"name":"Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Olsson-Brown","sequence":"additional","affiliation":[{"name":"Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Royal North Shore Hospital, Sydney, New South Wales, Australia"},{"name":"Mater Hospital, Sydney, New South Wales, Australia"},{"name":"Westmead and Blacktown Hospitals, Sydney, New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Malgeri","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Campus-Biomedico, Roma, Italy"},{"name":"Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom"},{"name":"Fondazione Policlinico Universitario Campus-Biomedico, Roma, Italy"},{"name":"Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafeh","family":"Naqash","sequence":"additional","affiliation":[{"name":"Medical Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences, Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"Royal North Shore Hospital, Sydney, New South Wales, Australia"},{"name":"Mater Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Challa","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailee","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Neurology, Northwestern University, Chicago, Illinois"},{"name":"Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"2","key":"zoi250455r1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/imm.13141","article-title":"Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.","volume":"159","author":"Fessas","year":"2020","journal-title":"Immunology"},{"issue":"16","key":"zoi250455r2","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018.","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"zoi250455r3","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations.","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"zoi250455r4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders.","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi250455r5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"zoi250455r6","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study.","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"issue":"7","key":"zoi250455r7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"zoi250455r8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jitc-2023-008724","article-title":"Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.","volume":"12","author":"Nassar","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"11","key":"zoi250455r9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s11910-023-01306-x","article-title":"Immune checkpoint inhibitors in patients with pre-existing neurologic autoimmune disorders.","volume":"23","author":"Aoun","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"zoi250455r10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"10","key":"zoi250455r11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.","volume":"9","author":"Halle","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6","key":"zoi250455r12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease.","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi250455r13","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy.","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"zoi250455r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120275","article-title":"Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases.","volume":"438","author":"Snavely","year":"2022","journal-title":"J Neurol Sci"},{"issue":"3","key":"zoi250455r15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1600-0404.2012.01667.x","article-title":"The recurrent Guillain-Barr\u00e9 syndrome: a long-term population-based study.","volume":"126","author":"Mossberg","year":"2012","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"zoi250455r16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.2008.156463","article-title":"Recurrent Guillain-Barr\u00e9 syndrome.","volume":"80","author":"Kuitwaard","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"zoi250455r17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1529-8027.2009.00243.x","article-title":"Recurrences, vaccinations and long-term symptoms in GBS and CIDP.","volume":"14","author":"Kuitwaard","year":"2009","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"zoi250455r18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1177\/1352458508088936","article-title":"Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark.","volume":"14","author":"Nielsen","year":"2008","journal-title":"Mult Scler"},{"issue":"1","key":"zoi250455r19","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16547","article-title":"Do immune checkpoint inhibitors affect the course of multiple sclerosis? a systematic review and meta-analysis.","volume":"32","author":"Gelibter","year":"2025","journal-title":"Eur J Neurol"},{"issue":"3","key":"zoi250455r20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200245","article-title":"Impact of immune checkpoint inhibitors on the course of multiple sclerosis.","volume":"11","author":"Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"zoi250455r21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/NRL.0b013e318251e6f2","article-title":"Clinical characteristics of exacerbations in Parkinson disease.","volume":"18","author":"Zheng","year":"2012","journal-title":"Neurologist"},{"issue":"12","key":"zoi250455r22","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study.","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"zoi250455r23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity.","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2834879\/fletcher_2025_oi_250455_1748437530.70094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:00:45Z","timestamp":1749034845000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2834879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.13727","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}